LON:NCYTNovacyt Share Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Novacyt SA Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add GBX 277.50 -0.50 (-0.18 %) (As of 07/9/2020 11:12 AM ET) Add Compare Share Today's Range 273Now: GBX 277.50▼ 28750-Day Range 215MA: GBX 271.74▼ 34552-Week Range 6.03Now: GBX 277.50▼ 529Volume249,631 shsAverage VolumeN/AMarket Capitalization£195.99 millionP/E RatioN/ADividend YieldN/ABetaN/A ProfileAdvanced ChartCompetitorsInsider TradesHeadlines Novacyt S.A. develops and sells diagnostic products for cancer and infectious diseases. The company's diagnostic products are used in liquid based cytology, oncology, microbiology, haematology, and serology testing. It offers NovaPrep, a liquid based cytology solution that is utilized in the diagnosis of cervical cancer; and clinical laboratory testing services to clinicians, healthcare providers, and patients. The company also develops, manufactures, and distributes diagnostic products for clinical and food laboratories; and manufactures and markets vitro diagnostic tests, as well as diagnostic reagents, test kits, and blood grouping reagents. It serves hospitals and large corporates. The company was founded in 2006 and is based in Vélizy-Villacoublay, France.Read More Beat the Market (BTM) Rank™ 0.0 Analyst's Opinion Consensus RatingThere is not enough analysis data for Novacyt. Previous Next 2.0 Community Rank Outperform VotesNovacyt has received 33 “outperform” votes. (Add your “outperform” vote.)Underperform VotesNovacyt has received 50 “underperform” votes. (Add your “underperform” vote.)Community SentimentNovacyt has received 60.24% “underperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Novacyt and other stocks. Vote “Outperform” if you believe NCYT will outperform the S&P 500 over the long term. Vote “Underperform” if you believe NCYT will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldNovacyt does not currently pay a dividend.Dividend GrowthNovacyt does not have a long track record of dividend growth. Previous Next 3.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Novacyt insiders have bought more of their company's stock than they have sold. Specifically, they have bought £70,641.05 in company stock and sold GBX 0 in company stock. Previous Next 0.0 Earnings and Valuation Price to Earnings Ratio vs. the MarketThe P/E ratio of Novacyt is -10.59, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Novacyt is -10.59, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioNovacyt has a P/B Ratio of 2.39. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next Analyst Opinion: 0.0Community Rank: 2.0Dividend Strength: 0.0Insider Behavior: 3.0Valuation: 0.0 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.00 out of 5 stars Industry, Sector and Symbol Stock Exchange LON Industry Biotechnology Sub-IndustryN/A SectorMedical Current SymbolLON:NCYT Previous Symbol CUSIPN/A CIKN/A Webwww.novacyt.com Phone33 1 39 46 51 04Debt Debt-to-Equity Ratio75.03 Current Ratio0.90 Quick Ratio0.52Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueGBX 116.20 per share Price / Book2.39Profitability EPS (Most Recent Fiscal Year)N/A Net IncomeN/A Net MarginsN/A Return on EquityN/A Return on AssetsN/AMiscellaneous Employees121 Outstanding Shares70,626,200Market Cap£195.99 million Next Earnings DateN/A OptionableNot Optionable LSE:NCYT Rates by TradingView Receive NCYT News and Ratings via Email Sign-up to receive the latest news and ratings for NCYT and its competitors with MarketBeat's FREE daily newsletter. Novacyt (LON:NCYT) Frequently Asked Questions How has Novacyt's stock been impacted by COVID-19 (Coronavirus)? Novacyt's stock was trading at GBX 107.50 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, NCYT shares have increased by 158.1% and is now trading at GBX 277.50. View which stocks have been most impacted by Coronavirus. Has Novacyt been receiving favorable news coverage? Media coverage about NCYT stock has trended negative this week, InfoTrie reports. The research firm ranks the sentiment of press coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. Novacyt earned a daily sentiment score of -2.1 on InfoTrie's scale. They also gave media headlines about the company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an effect on the stock's share price in the immediate future. View the latest news about Novacyt. Who are some of Novacyt's key competitors? Some companies that are related to Novacyt include Aptose Biosciences (APS), Oxford BioMedica (OXB), CEL-SCI (CVM), Cel-Sci (CVM), Paradigm Biopharmaceuticals (PAR), SIGA Technologies (SIGA), Biotest (BIO), Neptune Wellness Solutions (NEPT), Silence Therapeutics (SLN), TELIX Pharmaceutical (TLX), Starpharma (SPL), ProMetic Life Sciences (PLI), Pfenex (PFNX), IMV (IMV) and Altimmune (ALT). View all competitors. What other stocks do shareholders of Novacyt own? Based on aggregate information from My MarketBeat watchlists, some companies that other Novacyt investors own include Ecolab (ECL), Tiziana Life Sciences (TILS), Alacer Gold (ASR), Alliance Resource Partners (ARLP), Aquestive Therapeutics (AQST), Blue Apron (APRN), CELLECT BIOTECH/S (APOP), Amgen (AMGN), AEGON (AGN) and Adept Technology Group (ADT). Who are Novacyt's key executives? Novacyt's management team includes the following people: Mr. Graham Mullis, CEO & Director (Age 56)Mr. Anthony Dyer, CFO, Company Sec. & DirectorMs. Mandy Cowling, Corp. & Investor Relations Mang.Ms. Wendy Karban, Group HR Mang.Mr. Phillip Sefton, Managing Director of Lab21 Products Division What is Novacyt's stock symbol? Novacyt trades on the London Stock Exchange (LON) under the ticker symbol "NCYT." How do I buy shares of Novacyt? Shares of NCYT and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock. What is Novacyt's stock price today? One share of NCYT stock can currently be purchased for approximately GBX 277.50. How big of a company is Novacyt? Novacyt has a market capitalization of £195.99 million. Novacyt employs 121 workers across the globe. What is Novacyt's official website? The official website for Novacyt is www.novacyt.com. How can I contact Novacyt? The company can be reached via phone at 33 1 39 46 51 04. This page was last updated on 7/9/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
